Drug Profile
CR 8020
Alternative Names: Anti Flu Virus mAb40C7; CR-8020; Influenza monoclonal antibody 40C7; JNJ-54235051; Monoclonal antibody against influenza A viruses (CR8020) - CrucellLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator AIMM Therapeutics
- Developer Crucell
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Influenza virus haemagglutinin glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza A virus H3N2 subtype
- No development reported Influenza A virus infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 25 Mar 2019 Janssen Pharmaceutical terminates a phase I trial (In Volunteers) in Japan due to early positive results (NCT02015533)
- 05 May 2016 CR 8020 is still in phase II trials for Influenza-A virus H3N2 subtype (Prevention, In volunteers) in United Kingdom (IV)